Health news
A phase 3 trial evaluating tiragolumab in combination with atezolizumab (Tecentriq®) in adults with PD-L1 high locally advanced or metastatic non-small cell lung cancer (NSCLC) did not meet its coprimary endpoint of progression-free survival (PFS),…
The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Eli Lilly and Company regarding the Biologics License Application (BLA) for sintilimab in combination with pemetrexed and platinum chemotherapy for the…
The Food and Drug Administration (FDA) has accepted the New Drug Application for adagrasib for the treatment of patients with non-small cell lung cancer (NSCLC) harboring the KRASG12C mutation who have received at least 1…
The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for poziotinib for use in patients with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2…
The Food and Drug Administration (FDA) has granted accelerated approval to Exkivity (mobocertinib) for adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations,…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021